Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Traci Evans

Nurse Practitioner, Adult Health Gulfport, MS Nurse Practitioner

NPI 1982978771 CMS profile 10886261

4540 W Railroad St, Gulfport, MS 39501

Open in the dashboard

General payments

$8,179

456 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Traci Evans of Gulfport, MS is reported in the CMS Open Payments database as having received $8,179 across 456 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,165 60
2024 General $1,386 75
2023 General $1,715 93
2022 General $2,046 116
2021 General $1,867 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Traci Evans
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Traci Evans were reported at $1,165. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Traci Evans Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,867 $138 $43–$438 $132
2022 $2,046 $165 $54–$494 $149
2023 $1,715 $178 $61–$549 $160
2024 $1,386 $186 $62–$575 $164
2025 $1,165 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $1,088 68 payments
  2. Dexcom, Inc. $934 51 payments
  3. Abbott Laboratories $872 55 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $585 27 payments
  5. Medtronic, Inc. $572 32 payments
  6. Amgen Inc. $517 27 payments
  7. Xeris Pharmaceuticals, Inc. $497 24 payments
  8. Novo Nordisk Inc $433 25 payments
  9. Corcept Therapeutics $432 17 payments
  10. Sanofi-Aventis U.S. LLC $303 15 payments
  11. Other $1,945 115 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,179 456 payments
Products named General payments · program years 2021–2025
  1. FreeStyle Libre $872 55 payments
  2. Dexcom G6 Transmitter $838 46 payments
  3. Kerendia $585 27 payments
  4. JARDIANCE $530 36 payments
  5. Qutenza $469 27 payments
  6. Korlym $432 17 payments
  7. MOUNJARO $398 23 payments
  8. Prolia $395 21 payments
  9. EVENITY $388 22 payments
  10. MINIMED 780G $365 19 payments
  11. Other $4,312 240 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,251

Median for Nurse Practitioner: 389

Drug cost

$1,480,111

Median for Nurse Practitioner: $21,885

Branded share of claims

81%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 243 $310,023
Ozempic Semaglutide Brand 162 $203,820
Trulicity Dulaglutide Brand 137 $198,282
Jardiance Empagliflozin Brand 186 $181,803
Tresiba Flextouch U-200 Insulin Degludec Brand 81 $81,955
Tresiba Flextouch U-100 Insulin Degludec Brand 122 $71,349
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 74 $54,284
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 54 $51,058
Farxiga Dapagliflozin Propanediol Brand 36 $33,593
Prolia Denosumab Brand 18 $31,367

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$19,496

Medicare's payments for the services billed

Medicare patients

125

Average age 71

Services billed

431

78 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 55%
Chronic kidney disease 45%
Ischemic heart disease 44%
Depression 29%
COPD 26%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $214
$214 15 —
JARDIANCE
  • Lilly USA, LLC $150
$150 186 —
MOUNJARO
  • Lilly USA, LLC $88
$88 243 —
Qutenza
  • Averitas Pharma Inc. $87
$87 — —
RYBELSUS
  • Novo Nordisk Inc $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

456 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record